Your browser doesn't support javascript.
loading
تبين: 20 | 50 | 100
النتائج 1 - 1 de 1
المحددات
إضافة المرشحات








النطاق السنوي
1.
Medical Journal of the Islamic Republic of Iran. 2005; 19 (1): 7-12
ي الانجليزية | IMEMR | ID: emr-171206

الملخص

interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon [interferon alfa-2b] in combination with ribavirin as first-line treatment of chronic hepatitis C.A total of 97 treatment-naive patients received Heberon three million units thrice-weekly subcutaneously in combination with ribavirin for 12 months. Serum HCV RNA levels were measured before and during therapy and 6 months after the end of therapy. End-of-treatment and sustained virological responses was defined as an undetectable HCV-RNA level at the end of treatment, and 6 months after treatment was completed [end of follow-up], respectively.In an intent-to-treat analysis, HCV-RNA was undetectable at the end of treatment in 49.5% of patients. At the end of follow-up, sustained virological response was 36.1%. Combination treatment was generally well tolerated. Six patients stopped therapy because of side effects: severe cytopenia [n=4], depression [n=1], and hyperthyroidism [n=1]. Common side effects of therapy include: Flu-like syndrome [85.6%], generalized alopecia [41.2%], injection site inflammation [37.1%], mood changes [36%], anorexia [34%] and weight loss [32%].Heberon as an IFN product in combination with ribavirin for treatment of patients with chronic hepatitis C is relatively safe, feasible, and potentially efficacious. It has comparable results in achieving end-of-treatment and sustained viro-logical responses in chronic hepatitis C

اختيار الاستشهادات
تفاصيل البحث